公开(公告)号：EP4327823A1

公开(公告)日：2024-02-28

申请号：EP22791768.9

申请日：2022-04-21

申请人： Astellas Pharma Inc. ,  National Cancer Center

发明人： TENDA, Yoshiyuki ,  YURI, Masatoshi ,  YAGI, Shigenori ,  SATAKE, Yoshiki ,  HIRAYAMA, Kazunori ,  SHIRAI, Hiroki ,  SASAKI, Hiroki ,  CHIWAKI, Fumiko ,  KOMATSU, Masayuki

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C12N5/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/13 ,  C12N15/62 ,  C12N15/63 ,  C12P21/08

摘要： An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.
An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD 137 antibody binding to CD137 had agonistic activity for CD 137, promoted production of interferon y by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

公开(公告)号：EP3578560A1

公开(公告)日：2019-12-11

申请号：EP18747957.1

申请日：2018-02-01

申请人： Astellas Pharma Inc.

发明人： KURAMOTO, Kazuyuki ,  AKAIWA, Michinori ,  ABE, Tomoaki ,  ARAKI, Takanobu ,  YAMAKI, Susumu ,  KUNIKAWA, Shigeki ,  IMAIZUMI, Tomoyoshi ,  NIGAWARA, Takahiro ,  ARAKAWA, Keisuke ,  SHIMADA, Itsuro ,  SHIMAZAKI, Masashi ,  SATAKE, Yoshiki ,  WATANABE, Kazushi ,  KOIKE, Takanori

IPC分类号： C07D471/10 ,  A61K31/517 ,  A61P35/00

摘要： [Problem]
Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer.
[Means for Solution]
The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.